Giovanni Brandi
Born in Urbania (PU, Italy), 20/03/1955
Academic and professional qualifications
- Graduated in the Bologna University Medical School with honors
(110/110 cum laude) in 1988.
- Licensed to practice as MD in the Bologna University Medical
School in the first session of 1988
- Enrollment in the Bologna professional list of Physicians and
Surgeons since 05/21/1988, No 12489
- Specialization in Internal Medicine (70/70 cum laude) in
1996.
- PhD in "Biological Markers of tumors of the gastrointestinal
tract" in 1992 with a thesis entitled "Abnormal cell proliferation
as a marker of risk of rectal cancer of the large intestine"
- In 1991 Six month stage at the INRA in the “Unitè de
Physiologie et D'Ecologie du Système Digestif”, Jouy en Josas,
Paris, to study the problems of the intestinal microbiota in
relation to preneoplastic diseases of the gastrointestinal tract
and to learn the techniques of analysis of the gut microbiota using
germ-free animal models and gnotobiotic (ex germ-free associated to
known flora) applied to various diseases of the gastrointestinal
tract.
- One month stage about cronomodulation for the study of tumors
at the Service of Medical Oncology “Paul Brousse”, Villejuif
(Paris), directed by Dr. Francis Levi, in 1996.
- Medical Assistant of Internal Medicine in the Cesena hospital
from 13/03/2000 to 31/12/2000.
- Researcher of Medical Oncology in the department of Hematology
and Oncological Sciences of the Bologna University Medical School
from 01/01/2001 to 31/10/2010.
- Associate Professor of Medical Oncology in the department of
Hematology and Oncological Sciences of the Bologna University
Medical School from 01/11/2010 to present.
Institutional roles
- Member of the Collegio Superiore of the University of Bologna
(from November 2002 to present);
- Member of the Board of I.S.A. (Institute of Advanced Studies)
of the University of Bologna (from February 2013 to present);
- Member of the Board of I.S.S (Institute of Superior Studies) of
the University of Bologna (from November 2008 to present)
- Member of the Board of CINBO (National interuniversity
board for the Biotechnology) from 20/1/2014 to present
- Member of the Board of CIRC (Interdepartmental centre for
cancer research “G. Prodi” from 2001 to present
- Member of CRBA of the University of Bologna from 2010 to
present
- Referent Professor (University of Bologna) in the bilateral LL
/ ERASMUS agreements with the Semmelweis University (Hungary) and
the University Medical School in Poznan (Poland) (from November
2012 to the present)
- Director of the Specialization School in Medical Oncology
in Bologna from December 2010 to November 2013;
- Director of second level Master in Training and Qualification
in Palliative Care from July 2012 to present, sponsored by Isabella
Seragnoli-Hospice Foundation and University of Bologna.
- President of Gruppo Italiano Colangiocarcinoma- GICO
Teaching Activities
- Professor in the School of Specialization in Medical Oncology
at the University of Bologna since 2002
- Professor of Medical Oncology since 2013 in the Schools of
Specialization in: Medical Physics, Thoracic Surgery , Food
Science
- Professor of Medical Oncology in the Bologna University
Medical School as Professor of the course "Fundamentals in Oncology
" for the three-year course of "Technicians of Medical Radiology
and Radiotherapy " from 2004 to 2013; Professor of " Medical
Oncology " in the integrated courses of " Medical Sciences 4 "
(from 2004 to 2013) and " Medical Sciences 3 " (2013 -14) for the
master in Dietetic Science .
- Professor of the PhD in " Oncology, Methodology and Pathology
" of the University of Bologna since February 2014
- Professor at the Collegio Superiore of the University of
Bologna since 2002 (seminars and tutoring)
Membership
- Global Translational Medicine Consortium (GTMC), that is part
of the The European Society for Translational Medicine (EUSTM)
- AlmaSeq dell'Università di Bologna
- Bologna Liver Oncology Group (BLOG)
- Advisory Board – AstraZeneca (Selumetinibin BiliaryTract
Cancer)
- Clinical Responible for Nanotarget (Barcellona start up of
nanotechnology dedicated to the creation of oncology drugs conveyed
with nanogold)
- American Society of Clinical Oncology (ASCO)
- Member of the “Dyonisos Projet Group" epidemiological
research project on liver disease (1991-1996)
Peer review activities and editorial
board:
-
Reviewer for: NEJM (8 times from 2008 to 2013: articles on
hepatocarcinogenesis or treatment of HCC), Eur J Cancer; PlosOne;
Cancer Letter; Chemotherapy; J of Chem; Thromb Hemost; Int J of
Cancer, Oncology, Nat Clin Pract Gastroent, Indian Journal of
Medicine, Cancer.
- Member of editorial board of “Chinese Journal of Clinicians”
(International) and “Journal of Hematology and Thromboembolic
Diseases”, “Journal of Gastro: Open Access”, “Medicines”.
- In 2002, on behalf of the European Commission, the Italian
government and University of Bologna, he was evaluator for the
European funding of 700 projects of universities and scientific
research centres in Serbia. Reviewer of the oncologic projects
pertaining.
- In 2006, evaluator of the INSERM (France) project :
"Environmental factors and gastrointestinal carcinogenesis" 01EUEA_
scientific Project, PI Prof Iradj Sobhani.
Publications and congress activity
The writer is author of more than 100 papers in
international journals indexed (with IF> 500), 6 scientific
books, 9 book chapters, and he has been speaker and chairman at
national and international conferences
Awards
• For the book : " Ultrastructure microbienne Ecologie et du
Tube Digestif Humain " G Brandi , AM Flats , G Biasco, awarded in France during the
Ninth Edition of the International Scientific Paper (Deauville,
Normandy 5 to 7 June 1998) as the best work dedicated to continuing
medical education .
• PI of the poster : " Occupational exposure to asbestos : a
putative unknown risk factors for intrahepatic cholangiocarcinoma "
ILCA , Hong Kong , 2011 (ILCA Junior Investigator Award, given to
the co-author dr. S. Di Girolamo)
International collaborations
- 2012 – to present: collaboration with the institute INRA , Jouy
en Josas , and the Hospital Saint Antoine, Paris (France) ( Dr. P.
Langella , Dr. Henry Sokol ) for the study of intestinal microbiota
in the genesis of colorectal cancer
- 2012 – to present: collaboration with CIRM in Marseille, France
(Prof. G. Chapuisat and Prof. P. Sicbaldi ), for the creation of
mathematical models of standardization of therapeutic strategies in
patients with advanced carcinoma of the colon .
- 2013 – to present: collaboration with the cancer registry of
northern Europe (NOCCA) in particular with Professor Eeron Pukkala,
to evaluate the role of asbestos in carcinogenesis of the biliary
tract
- 2013 – to present: Collaboration with Mayo Clinic (Rochester ,
USA ), Cornell University (NY , USA), Christie Hospital
(Manchester, UK), Tokio University and Singapore University, for
writing the book " Cholangiocarcinoma " - Nova Science Publisher,
New York , planned publication in October 2014 (Giovannii Brandi
& Giorgio Ercolani editors).
Responsibility for scientific research projects funded on
the basis of competitive calls
• 2000 - Young Researchers UNIBO : "Role of the human intestinal
microflora in the toxicity induced by CPT-11 using germ-free mice and eteroxenic model " (
7.5 million pounds ) (12 months , PI)
• 2003 - FIRB : "Design and synthesis of new
radiopharmaceuticals for molecular recognition of onco -
hematological and endocrine-metabolic pathologies using
high-throughput imaging method in vivo (micro- PET) (share Unit
: EUR 228,000 ) ( 36 months duration , co -PI of units)
• 2005 - PRIN : " Liver metastases from colorectal cancer : risk
factors, prognosis, and treatment on molecular basis " ( 87 143
euro ) ( 36 months duration , co -PI of units)
• 2006/2012- RFO Unibo ( total amount of EUR 59 520 ) (one-year
programs, PI)
• 2010-2012 - Region - University Program: "Innovative
approaches to the diagnosis and pharmacogenetic - based therapies
of primary hepatic Tumours , peripheral B and T -cell lymphoblastic
lymphomas and leukaemias " ( 75.000 € ) ( 36 months duration , co-
PI of Work Pakage 3 and 4)
• 2013 – Del Monte Foundation: "Searching for genetic markers of
asbestos exposure in patients with intrahepatic cholangiocarcinoma
using next generation sequencing technology " (€ 23,000 ) (12
months , PI)
Areas of Clinical Activities and Management
The writer is devoted to care activities as part of the
agreement between the University of Bologna and S. Orsola -Malpighi
Hospital as the medical staff of the NHS : Medical Doctor from
01.01.2002 to present.
The activity of the medical oncologist has been always carried
out as part of the " Biasco" Unit.
Here (as certified by the head of the Unit) conducted
exclusively the activity of DH and ambulatory of general oncology
until the end of 2006, since then he has integrated it with the the
care of specifically selected patients with primary and secondary
liver tumors, seeing about 60 new HCC, 50 cholangiocarcinomas , 40
liver metastases from colorectal cancer and about 20 NET per year.
He dedicate a portion of its activity also to neoplasia of the
pancreas, in collaboration with other colleagues in the Unit.
This clinical activity takes place in complete harmony with the
other structures of the Hospitals, primarily surgeries (
hepatobiliary and colorectal ) , the interventional radiology ,
pathologists and radiotherapists . Interesting to note that the
management of the epatobiliopancreatic disease and transplantation
is one of the strategic areas of the S. Orsola -Malpighi
Hospital.
In addition, since 2004, first as secretary and then as Director
of the School of Specialization in Medical Oncology (November 2010
- November 2013), he was devoted to training and managing
activities of dozens of young oncologists. In this perspective, the
writer has tried to teach the younger colleagues a method of
scientific and clinical reasoning that would allow them to cope
with the rapid changes in the future of medical oncology. The fact
that most of our former interns have easily found a job and that
their skills are widely appreciated in the structures in which they
currently operate, supports the vitality of our graduate school. It
has also been recognized by the region that for the academic year
2013-2014 has funded an extra scholarship.
The writer has also involved the interns in drafting the book "
Follow-up in Oncology " for the Bologna University Press,
that will be published in the coming months.
PUBLICATIONS:
Prevalence of and risk factors for hepatic steatosis in Northern
Italy S Bellentani, G Saccoccio, F Masutti, LS Crocè… - Annals
of internal medicine, 2000
The key role of segmented filamentous bacteria in the coordinated
maturation of gut helper T cell responses V Gaboriau-Routhiau,
S Rakotobe, E Lécuyer, I Mulder… - Immunity, 2009
Drinking habits as cofactors of risk for alcohol induced liver
damage S Bellentani, G Saccoccio, G Costa, C Tiribelli… - Gut,
1997
High prevalence of celiac disease in Italian general population
U Volta, S Bellentani, FB Bianchi, G Brandi… - Digestive diseases
and sciences, 2001
Interactions between commensal bacteria and gut sensorimotor
function in health and diseaseG Barbara, V Stanghellini, G
Brandi, C Cremon… - The American journal of gastroenterology,
2005
Effect of vitamin A, C, and E supplementation on rectal cell
proliferation in patients with colorectal adenomas GM
Paganelli, G Biasco, G Brandi, R Santucci, G Gizzi… - Journal of
the National Cancer Institute, 1992
Hypersensitivity reactions related to oxaliplatin (OHP) G
Brandi, MA Pantaleo, C Galli, A Falcone… - British journal of
cancer, 2003
Treatment of hepatic metastases from colorectal cancer: many
doubts, some certainties
G Biasco, E
Derenzini, GL Grazi, G Ercolani, M Ravaioli… - Cancer treatment
reviews, 2006
Metastatic pancreatic cancer: Is gemcitabine still the best
standard treatment?(Review)
M Di Marco, R Di Cicilia,
M Macchini, E Nobili… - Oncology reports, 2010
Intrahepatic cholangiocarcinoma: primary liver resection and
aggressive multimodal treatment of recurrence significantly prolong
survival G Ercolani, G Vetrone, GL Grazi, O Aramaki, M Cescon…
- Annals of surgery, 2010
Rectal cell proliferation and colon cancer risk in patients with
hypergastrinaemia M Renga, G Brandi, GM Paganelli, C
Calabrese… - Gut, 1997
Molecular pathways involved in colorectal cancer: implications for
disease behavior and prevention D Colussi, G Brandi, F Bazzoli,
L Ricciardiello - International journal of molecular
sciences, 2013
Effect of lactobacillus acidophilus and bifidobacterium bifidum on
rectal cell kinetics and fecal pH. G Biasco, GM Paganelli, G
Brandi, S Brillanti, F Lami… - The Italian journal of
gastroenterology, 1991
Ano-rectal lesions in patients taking suppositories containing
non-steroidal anti-inflammatory drugs (NSAID). G Gizzi, V
Villani, G Brandi, GM Paganelli, G Di Febo… - Endoscopy, 1990
Rectal cell proliferation and colorectal cancer risk level in
patients with nonfamilial adenomatous polyps of the large bowel
GM Paganelli, G Biasco, R Santucci, G Brandi, AA Lalli… - Cancer,
1991
Correlation between endoscopic features of gastric antrum,
histology and Helicobacter pylori infection in adults. C
Calabrese, G Di Febo, G Brandi, AM Morselli-Labate… - Italian
journal of gastroenterology and …, 1998
Changes in the surgical approach to hilar cholangiocarcinoma during
an 18‐year period in a Western single center G Ercolani, M
Zanello, GL Grazi, M Cescon, M Ravaioli… - Journal of
hepato-biliary-pancreatic sciences, 2010
Colorectal cancer in patients with ulcerative colitis. A
prospective cohort study in
Italy G
Biasco, G Brandi, GM Paganelli, FP Rossini… - Cancer, 1995
Urease-positive bacteria other than Helicobacter pylori in human
gastric juice and mucosa G Brandi, B Biavati, C
Calabrese, M Granata… - The American journal of gastroenterology,
2006
Gene expression profiling of liver metastases from colorectal
cancer as potential basis for treatment choice MA Pantaleo, A
Astolfi, M Nannini, P Paterini, G Piazzi… - British journal of
cancer, 2008
Intestinal microflora and digestive toxicity of irinotecan in
mice. G Brandi, J Dabard, P Raibaud, M Di Battista… - Clinical
cancer research, 2006
Clinical, pharmacokinetic and pharmacodynamic evaluations of
metronomic UFT and cyclophosphamide plus celecoxib in patients with
advanced refractory gastrointestinal cancers G Allegrini, T Di
Desidero, MT Barletta, A Fioravanti… - Angiogenesis, 2012
Lack of association with spondyloarthritis and HLA-B27 in Italian
patients with Whipple's disease. I Olivieri, G Brandi, A
Padula, M Di Stefano… - The Journal of rheumatology, 2001
Surgical debulking of gastrointestinal stromal tumors: is it a
reasonable option after second-line treatment with sunitinib?
MA Pantaleo, M Di Battista, F Catena, M Astorino… - Journal of
cancer research and clinical …, 2008
Bifidobacterium animalis protects intestine from damage induced by
zinc deficiency in rats E Mengheri, F Nobili, F
Vignolini, M Pesenti, G Brandi… - The Journal of nutrition,
1999
Neoadjuvant treatment in rectal cancer: actual status I
Garajová, S Di Girolamo, F de Rosa, J Corbelli… - Chemotherapy
research and practice, 2011
Cancer surveillance in ulcerative colitis: critical analysis of
long-term prospective programme G Biasco, FP Rossini, R Hakim,
G Brandi, M Di Battista… - Digestive and Liver Disease,
2002
Molecular imaging and targeted therapies in oncology: new concepts
in treatment response assessment. a collection of cases MA
Pantaleo, M Nannini, E Lopci, P Castellucci… - International
journal of oncology, 2008
Chemoprevention of colorectal cancer: role of antioxidant
vitamins. G Biasco, GM Paganelli, G Brandi, R Santucci, AA
Lalli… - European Journal of Cancer Prevention, 1992
Cold single-strand conformation polymorphism analysis: optimization
for detection of APC gene mutations in patients with familial
adenomatous polyposis P Strippoli, S Sarchielli, R Santucci, GP
Bagnara… - International journal of molecular medicine,
2001
Circadian variations of rectal cell proliferation in patients
affected by advanced colorectal cancer G Brandi, C Calabrese,
MA Pantaleo, AM Labate… - Cancer letters, 2004
Metronomic capecitabine in advanced hepatocellular carcinoma
patients: a phase II study G Brandi, F De
Rosa, V Agostini, S Di Girolamo… - The oncologist, 2013
To widen the setting of cancer patients who could benefit from
metronomic capecitabine M
Nannini, E Nobili, R Di Cicilia, G Brandi, A Maleddu… - Cancer
chemotherapy and pharmacology, 2009
Cell renewal and cancer risk of the stomach: analysis of cell
proliferation kinetics in atrophic gastritis. G Biasco, GM
Paganelli, S Brillanti, AA Lalli, G Brandi… - Acta
gastro-enterologica Belgica, 1988
Activated NF-kB in colorectal cancer: predictive or prognostic
factor? G Brandi, MA Pantaleo, G Biasco, P Paterini - Journal
of Clinical Oncology, 2008
Cell proliferation and ultrastructural changes of the duodenal
mucosa of patients affected by familial adenomatous polyposis G
Biasco, G Cenacchi, E Nobili, MA Pantaleo… - Human pathology,
2004
Durable complete response of hepatocellular carcinoma after
metronomic
capecitabine
G Brandi, F de Rosa, L Bolondi, V Agostini… - Tumori, 2010
Antitumoral efficacy of the protease inhibitor gabexate mesilate in
colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations G
Brandi, S Tavolari, F De Rosa, S Di Girolamo… - PloS one, 2012
Port a Cath related complications in 252 patients with solid tissue
tumours and the first report of heparin‐induced delayed
hypersensitivity after Port a Cath... I Garajová, G Nepoti, M
Paragona, G Brandi, G Biasco - European journal of cancer care,
2013
Impact of surgery on the development of duodenal cancer in patients
with familial adenomatous polyposis G Biasco, E Nobili, C
Calabrese, R Sassatelli… - Diseases of the colon & rectum,
2006
Methodological problems in the use of rectal cell proliferation as
a biomarker of colorectal cancer risk. G Biasco, GM Paganelli,
R Santucci, G Brandi… - Journal of cellular biochemistry.
Supplement, 1993
Discrepancy between declared and recovered bifidobacteria in a
human probiotic P Mattarelli, G Brandi, M Modesto,
B Biavati - Annals of microbiology, 2002
Exocrine-Endocrine Pancreatic Cancer and α-Fetoprotein G
Brandi, E Nobili, E Capizzi, B Corti, R Di Cicilia… - Pancreas,
2008
Abnormal rectal cell proliferation and p52p35 protein expression in
patients with ulcerative colitis GM Paganelli, PJ Higgins, G
Biasco, M Lipkin, G Brandi… - Cancer letters, 1993
Asbestos: a hidden player behind the cholangiocarcinoma increase?
Findings from a case–control analysis G Brandi, S Di Girolamo,
A Farioli, F de Rosa, S Curti… - Cancer Causes & Control,
2013
Effectiveness and cost-effectiveness of peri-operative versus
post-operative chemotherapy for resectable colorectal liver
metastases G Ercolani, A Cucchetti, M Cescon, E Peri, G Brandi…
- European Journal of Cancer, 2011
Multivariate prognostic factors analysis for second-line
chemotherapy in advanced biliary tract cancer L Fornaro, S
Cereda, G Aprile, S Di Girolamo, D Santini… - British journal of
cancer, 2014
ANALYSIS OF ILEAL BACTERIAL-FLORA IN PATIENTS WITH ILEAL-ANAL
ANASTOMOSIS WITH AND WITHOUT POUCHITIS G Brandi, S Chaussade, M
Ladire, J Nicoli… - Gut, 1992
Correlation between bromodeoxyuridine labelling and ornithine
decarboxylase levels in normal rectal mucosa of patients with
colorectal adenoma GM Paganelli, G Saccoccio, G Brandi, S
Bellentani… - Cancer letters, 1991
Molecular imaging suggests efficacy of bevacizumab beyond the
second line in advanced colorectal cancer patients G Brandi, M
Nannini, MA Pantaleo, S Fanello… - Chemotherapy, 2008
Venous thromboembolism and port-related thrombosis in metastatic
colorectal cancer patients: a monocenter experience E Nobili, R
Di Cicilia, M Di Battista, AM Morselli-Labate… - Pathophysiology of
haemostasis and …, 2009
Adjuvant systemic chemotherapy after putative curative resection of
colorectal liver and lung metastases G Brandi, E Derenzini, A
Falcone, G Masi, F Loupakis… - Clinical colorectal cancer,
2013
HIV enteropathy: undescribed ultrastructural changes of duodenal
mucosa and their regression after triple antiviral therapy. A case
report G Brandi, C Calabrese, R Manfredi, AM Pisi, G Di Febo… -
Digestive diseases and sciences, 2005
A phase I study of continuous hepatic arterial infusion of
Irinotecan in patients with locally advanced hepatocellular
carcinoma G Brandi, G Biasco, MG Mirarchi, R Golfieri, A Di
Paolo… - Digestive and Liver Disease, 2011
Flow cytometry and in vitro tritiated thymidine labeling in normal
rectal mucosa of patients at high risk of colorectal cancer. GM
Paganelli, E Lalli, A Facchini, G Biasco, R Santucci… - The
American journal of gastroenterology, 1994
Integrated genomic study of quadruple-WT GIST (KIT/PDGFRA/SDH/RAS
pathway wild-type GIST)(quadrupleWT, or
KITWT/PDGFRAWT/SDHWT/RAS-PWT GIST) M Nannini, A Astolfi, M
Urbini, V Indio, D Santini… - BMC cancer, 2014
Bacteria in biopsies of human hypochloridric stomach: a scanning
electron microscopy study G Brandi, A Pisi, G Biasco, M
Miglioli, B Biavati… - Ultrastructural pathology, 1996
Complete remission of primary colon cancer in a metastatic patient
treated with CPT-11 plus capecitabine G Brandi, MA Pantaleo, C
Calabrese, M Di Battista… - International journal of colorectal
disease, 2004
Metronomic capecitabine in advanced patients with hepatocellular
carcinoma (HCC): Preliminary results G Brandi, S Fanello, F
Piscaglia, A Falanga, L Bolondi… - ASCO Annual Meeting Proceedings,
2007
Esposizione all'amianto in pazienti affetti da neoplasie delle vie
biliari Asbestos exposure in patients affected by bile duct
tumours G Brandi, S Di Girolamo, F Belpoggi, G Grazi… - Eur. J.
Oncol, 2008
Rectal cell proliferation as an intermediate biomarker of risk of
colorectal cancer.G Biasco, GM Paganelli, G Brandi, R Santucci…
- European journal of cancer prevention, 1993
Second-line chemotherapy in patients with biliary tract cancer.
G Brandi, S Di Girolamo, F De Rosa, J Corbelli… - ASCO Annual
Meeting Proceedings, 2011
Unresectable perihilar cholangiocarcinoma: multimodal palliative
treatment C Mosconi, M Renzulli, E Giampalma, A Galuppi… -
Anticancer research, 2013
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy
in cirrhotic patients? G Brandi, F
Rosa, L Calzà, SD Girolamo, M Tufoni… - Liver International,
2013
Cutaneous leukocytoclastic vasculitis due to erlotinib: just an
adverse event or also a putative marker of drug efficacy? G
Brandi, M Venturi, E Dika, H Maibach, A Patrizi… - Cutaneous and
ocular toxicology, 2013
Second surgery or chemotherapy for relapse after radical resection
of colorectal cancer metastases G Brandi, J Corbelli, F de
Rosa, S Di Girolamo… - Langenbeck's Archives of Surgery,
2012
Durable complete response to frontline docetaxel in an advanced
prostate cancer patient with favourable CYP1B1 isoforms: suggestion
for changing paradigms? G Brandi, F de Rosa, R Danesi, GC
Montini, G Biasco - European urology, 2008
Gene expression profiling differences between synchronous and
metachronous liver metastases of colorectal cancer MA Pantaleo,
A Astolfi, M Nannini, G Ercolani, G Brandi… - Molecular Cancer
Therapeutics, 2007
Irinotecan toxicity: genes or intestinal microflora? G Brandi,
F de Rosa, G Biasco - British journal of cancer, 2009
Lessons from the Fourth Metronomic and Anti-angiogenic Therapy
Meeting, 24–25 June 2014, Milan G Bouche, N André, S Banavali,
F Berthold, A Berruti… - ecancermedicalscience, 2014
[Treatment of colorectal cancer liver metastases] E Derenzini,
M Di Battista, MC Di Marco, S Dell'Arte… - Minerva medica, 2006
Cutaneous adverse reactions linked to targeted anticancer therapies
bortezomib and lenalidomide for multiple myeloma: new drugs, old
side effects A Patrizi, M Venturi, E Dika, H Maibach, P
Tacchetti… - Cutaneous and ocular toxicology, 2014
Synbiotic yogurt consumption by healthy adults and the elderly: the
fate of bifidobacteria and LGG probiotic strain M Granata, G
Brandi, A Borsari, R Gasbarri, DD Gioia - International journal of
food sciences and …, 2013
Risk of duodenal cancer in patients with familial adenomatous
polyposis G Biasco, MA Pantaleo, G Di Febo, C Calabrese… - Gut,
2004
Is there a relationship between hypergastrinemia and colorectal
cancer risk? Rectal cell proliferation in Zollinger-Ellison
syndrome. G Biasco, G Brandi, M Renga, GM Paganelli… - The
American journal of gastroenterology, 1995
CS. 01.3 THE EMERGING IMPACT OF HCC-NAFLD IN ITALY S
Bellentani, A Barchetti, E Dionigi, A Fracanzani… - Digestive and
Liver Disease, 2012
THE RELATIONSHIP BETWEEN TYPE-A AND TYPE-B GASTRITIS AND
HELICOBACTER-PYLORIG Biasco, GM Paganelli, R Santucci, G
Brandi… - EUROPEAN JOURNAL OF …, 1993
The emerging role of 3D and 2D contrast-enhanced ultrasound with
quantitative analysis in evaluating the response to new antitumoral
treatments C Serra, G Brandi - Medicamundi, 2007
Occurrence of Bifidobacteriaceae in human hypochlorhydria
stomach P Mattarelli, G Brandi, C Calabrese, F Fornari, GM
Prati… - Microbial ecology in health and disease, 2014
Metronomic capecitabine as second-line treatment for patients with
hepatocellular carcinoma with preserved liver function: A phase II
study. F De Rosa, V Agostini, S Di Girolamo, P Andreone… - ASCO
Annual Meeting Proceedings, 2011
Systemic adjuvant chemotherapy after resection of colorectal cancer
metastases G Brandi, E Derenzini, MA Pantaleo, M Di Battista… -
ANNALS OF ONCOLOGY, 2004
Mutagenic and clastogenic activity of gastric juice in human
gastric diseases P Hrelia, C Fimognari, F Maffei, G Brandi, G
Biasco… - Mutation Research/Genetic Toxicology and …,
2002
CASE REPORT: Severe and Relapsing Upper Gastrointestinal Bleeding
in a Patient with Glanzmann's Thrombasthenia C Calabrese, G Di
Febo, A Areni, MC Morelli, C Scialpi… - Digestive diseases and
sciences, 2000
Antiprotease Strategy in Pancreatic Cancer Treatment: Emergence
From a Preclinical Study G Brandi, S Tavolari, T Guarnieri, M
Di Marco… - Pancreas, 2014
Cell kinetics of the gastric mucosa of patients treated with
omeprazole. G Biasco, P Mordenti, G Brandi, GM Paganelli… - The
American journal of gastroenterology, 1996
Safety of hepatic resection for colorectal metastases in the era of
neo-adjuvant chemotherapy A Cucchetti, G Ercolani, M Cescon, P
Di Gioia, E Peri… - Langenbeck's Archives of Surgery,
2012
Second-line chemotherapy in advanced biliary cancer: the present
now will later be
past C Vivaldi, L
Fornaro, S Cereda, G Aprile, D Santini… - Annals of Oncology,
2014
Is adjuvant systemic chemotherapy after resection of metastases
from colorectal cancer suitable? MA Pantaleo, G Brandi, E
Derenzini, S Fanello… - ASCO Annual Meeting Proceedings, 2004
Bacterial colonization in juice and biopsies of the achlorhydric
stomach G Brandi, G Biasco, B Biavati, GM Paganelli, C Masci… -
Gastroenterology, 1995
Chemotherapy followed by chemoradiotherapy in locally advanced
pancreatic cancer: A literature review and report of two cases
M Di Marco, M Macchini, S Vecchiarelli, R Casadei… - Oncology
letters, 2011
Preliminary results of metronomic capecitabine treatment in
advanced hepatocellular carcinoma (HCC) G Brandi, S Fanello, F
Piscaglia, A Falanga, D Balducci… - ANNALS OF ONCOLOGY,
2007
GEMOX as first-line chemotherapy in advanced pancreatic cancer
(APC): A monoinstitutional experience M Di Marco, E Nobili, R
Di Cicilia, G Brandi, S Bertolini… - ASCO Annual Meeting
Proceedings, 2007
Re: Effect of simvastatin on cetuximab resistance in human
colorectal cancer with KRAS mutations G Brandi, G Biasco, S
Tavolari - Journal of the National Cancer Institute, 2011
Effect of the serine proteases inhibitor gabexate mesylate (GM) on
the activity of gemcitabine (G) in cell lines of pancreatic cancer
(PC) G Brandi, P Paterini, S Tavolari, G Da Pozzo, E Nobili… -
ASCO Annual Meeting Proceedings, 2009
Impact of adjuvant chemotherapy on time to relapse in
cholangiocarcinoma. S Di Girolamo, E Nobili, E Derenzini, F de
Rosa… - ASCO Annual Meeting Proceedings, 2011
Bifidobacteria: Microbiological Aspects and Probiotic
Potentialities G Brandi, B Biavati, G Biasco - 2003
Risk of duodenal adenomas in familial adenomatous polyposis to
progress toward advanced neoplastic disease G Biasco, MA
Pantaleo, G Di Febo, C Calabrese… - Journal of clinical oncology,
2004
Dose response effects of 2-acetylaminofluorene on DNA damage,
cytotoxicity, cell proliferation and neoplastic conversion in rat
liver T. Umemura, K. Tokumo, H. Sirma, R.... Y Kataoka, T
Matsumura, S Yamamoto, T Sugimoto… - Cancer Letters, 1993
Triple therapy with azithromycine, lansoprazole and tinidazole is
highly effective in the eradication of Helicobacter pylori: A pilot
(open) study G DiFebo, C Calabrese, G Brandi, A Areni, A Muia…
- GUT, 1997
Eparine a basso peso molecolare e sopravvivenza in pazienti con
cancro. Selezione di casi e revisione della letteratura Low
molecular weight heparins and survival in cancer...G Brandi, S
Di Girolamo, V Agostini, R Di Cicilia… - Eur. J. Oncol,
2008
Clinical patterns of hepatocellular carcinoma (HCC) in non
alcoholic fatty liver disease (NAFLD): a multicenter case-control
study F Piscaglia, GS Baroni, A Barchetti, A Pecorelli… -
Digestive and Liver Disease, 2015
News| ForumNO Witherspoon, E Janus, MT Martin, DJ Dix, G
Brandi…
Liver metastases from colorectal cancer G Biasco, E Derenzini,
S Fanello, G Brandi - EUROPEAN JOURNAL OF ONCOLOGY, 2005
20 P Omeprazole therapy induce the ultrastructural healing in acid
reflux oesophagitis. A preliminary report C Calabrese, M
Bortolotti, A Fabbri, A Areni… - Digestive and Liver Disease,
2002
Antiprotease strategy in combination with gemcitabine as a putative
novel therapeutic approach for pancreatic cancer treatment M
Macchini, G Brandi, S Tavolari, T Guarnieri… - Pancreatology,
2012
Phase I/II trial of continuous hepatic arterial infusion (HAI) of
Irinotecan in patients with hepatocellular carcinoma (HCC).
Preliminary results M Pantaleo, E Derenzini, F Piscaglia, R
Golfieri… - ASCO Annual Meeting Proceedings, 2006
Impact of surgery and chemotherapy on survival in
cholangiocarcinoma G Brandi, E Derenzini, E Nobili, MC Di
Marco… - ANNALS OF ONCOLOGY, 2005
Follow-up in oncologia G Brandi, G Biasco - 2015
Effect of folate and a-lipoic acid supplementation on rectal
mucosal cell kinetics M Di Marco, R Di Cicilia, M Di Battista,
G Brandi… - ANNALS OF ONCOLOGY, 2006
High prevalence of asbestos exposure in bile duct cancer
patients. S Di Girolamo, F de Rosa, E Nobili, V Agostini… -
ASCO Annual Meeting Proceedings, 2010
Some pathological features of Giardia infecting the human small
intestine observed at SEM A Pisi, G Brandi, G Filippini, G
Biasco, C Calabrese…
Correspondence-in-Press E Janus, G Brandi, E Nobili, SD
Girolamo, G Grazi…
METRONOMIC CAPECITABINE IN HEPATOCELLULAR CARCINOMA RELAPSE AFTER
LIVER TRANSPLANTATION: A RETROSPECTIVE STUDY F de Rosa, V
Agostini, M Ravaioli, M Cescon, GL Grazi… - ANNALS OF ONCOLOGY,
2009
Preliminary report on a phase I/II trial of continuos hepatic
arterial infusion (HAI) of irinotecan (CPT-11) in patients (PTS)
with locally advanced hepatocellular carcinoma (HCC) F
Piscaglia, MG Mirarchi, E Derenzini, A Lanzi… - HEPATOLOGY,
2006
Dystrophin deregulation is associated with tumor progression in
KIT/PDGFRA mutant gastrointestinal stromal tumors MA Pantaleo,
A Astolfi, M Urbini, F Fuligni, M Saponara… - Clinical sarcoma
research, 2014
Gene expression profiling of liver metastases from colorectal
cancer: differences between synchronous and metachronous
lesions MA Pantaleo, A Astolfi, M Nannini, P Paterini, G
Piazzi… - ASCO Annual Meeting Proceedings, 2008
The Best Management of Portal Neoplastic Thrombosis in
Hepatocellular
Carcinoma
G Brandi, S De Lorenzo, M Venturi, J Corbelli, G Frega… - 2014
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and
celecoxib in patients with advanced gastrointestinal cancers: A
clinical study with pharmacokinetic (PK)... G Allegrini, G
Bocci, M Barletta, A Fioravanti… - ANNALS OF ONCOLOGY,
2008
Low molecular weight heparins and survival in cancer patients. Case
collection and review of the literature G Brandi, S Di
Girolamo, V Agostini, R Di Cicilia - European Journal of Oncology,
2008
Carboplatin (CBDCA) and paclitaxel (TAX) as induction chemotherapy
in stage IIIA–IIIB in non small cell lung cancer (NSCLC) S
Tamberi, E Gallerani, R Bazzocchi, M Zompatori… - European Journal
of Cancer, 1999
Extrahepatic Feeding of HCC Limits the Use of TACE? Evidences from
Literature and Clinical Experience A Tovoli, L Napoli, M
Mastroroberto, M Renzulli… - 2013
Il trattamento delle metastasi epatiche da cancro del
colon-retto E Derenzini, M Di Battista, MC Di Marco, S
DELL'ARTE… - Minerva medica, 2006
THE PROTEASE INHIBITOR GABEXATE MESYLATE HAS ANTI-TUMOR EFFECTS AND
ENHANCES GEMCITABINE ACTION ON PANCREATIC CANCER CELL LINES G
Brandi, S Tavolari, P Paterini, F de Rosa… - ANNALS OF ONCOLOGY,
2009
Familial adenomatous polyposis (FAP): Dysplasia and pouchitis of
the pouch after ileal pouch-anal anastomosis (IPAA) C
Calabrese, G Di Febo, A Areni, E Nobili, G Brandi… -
Gastroenterology, 2000
Endoscopy fails in identifying the presence of Helicobacter pylori
(Hp) in gastric antrum of adults G Di Febo, C Calabrese, G
Brandi, AM Morselli-Labate… - Gastroenterology, 1998
Dyskerin expression in human fetal, adult and neoplastic
intrahepatic bile ducts: correlations with cholangiocarcinoma
aggressiveness F Vasuri, L Rocchi, A Degiovanni, F Giunchi, G
Brandi… - Histopathology, 2015
Phase I/II trial of continuous hepatic arterial infusion (HAI) of
irinotecan in patients with hepatocellular carcinoma (HCC).
Preliminary results G Brandi, E Derenzini, MA Pantaleo, F
Piscaglia… - ANNALS OF ONCOLOGY, 2006
BACTERIAL-FLORA OF THE ILEAL RESERVOIR AFTER ILEAL-ANAL ANASTOMOSIS
IN PATIENTS WITH AND WITHOUT POUCHITIS G Brandi, S CHAUSSADE, M
LADIRE, J NICOLI… - GASTROENTEROLOGY, 1993
The Editors wish to thank the following individuals who have
assisted the Journal of Chemotherapy in 2009 with the critical task
of reviewing and screening articles submitted... D
Adam, C Adembri, L Aguilar, G Amicosante…
KRAS and BRAF mutational status as selective criteria for targeted
therapy in cholangiocarcinoma. G Brandi, M Fiorentino, S Di
Girolamo, F de Rosa… - ASCO Annual Meeting Proceedings,
2010
Colorectal Cancer in Patients with Ulcerative Colitis G Biasco,
G Brandi, GM Paganelli, FP Rossini…
Breast carcinoma presenting as linitis plastica G Brandi, E
Campadelli, E Nobili, O Leone - Digestive and Liver Disease,
2010
Second-line chemotherapy for advanced biliary tract cancer: Results
of a multicenter surveyE Vasile, S Di Girolamo, S Cereda, S
Lonardi, F Leone… - EUROPEAN JOURNAL OF CANCER, 2013
Cancer Letters, Vol. 60, No. i, October 1991 C Fernandes, KVK
Rao, GM Paganelli, G Saccoccio… - Toxicology, 1991
The risk of duodenal cancer in familial adenomatous polyposis
(FAP) G Biasco, R Sassatelli, E Nobili, L Camellini… - ANNALS
OF ONCOLOGY, 2005
Colite ulcéreuse chronique et cancer colorectal G Biasco, GM
Paganelli, G Brandi, M Miglioli… - Acta endoscopica, 1995
IMPACT OF MULTIDISCIPLINARY APPROACH ON SURVIVAL OF PATIENTS WITH
KLATSKIN TUMOR S Di Girolamo, V Agostini, E Nobili, F De Rosa…
- ANNALS OF ONCOLOGY, 2009
Genomic and Genetic Characterization of Cholangiocarcinoma
Identifies Therapeutics Targets for Tyrosine Kinase Inhibitors
G Brandi, S Tavolari, G Biasco - Gastroenterology, 2012
21 P Dilated intercellular spaces of human oesophageal epithelium
as the first and most sensitive marker of damage in acid reflux
oesophagitis C Calabrese, M Bortolotti, A Fabbri, A Areni… -
Digestive and Liver Disease, 2002
After surgery surveillance in high risk colorectal cancer
patients R Santucci, B Poggi, L Volpe, C Calabrese, P Mordenti…
- ANNALS OF ONCOLOGY, 1998
Plasma membrane localization of human equilibrative nucleoside
transporter 1 (hENT-1) to predict better outcome of adjuvant
gemcitabine in cholangiocarcinoma (CC) patients.
G
Brandi, S Tavolari, F Vasuri, A Farioli, M Deserti… - JOURNAL OF
CLINICAL ONCOLOGY, 2013
Gastrointestinal stromal tumors: A monoinstitutional experience
M Di Battista, MA Pantaleo, M Astorino, G Brandi… - ASCO Annual
Meeting Proceedings, 2007
Lipohyperplasia of the ileocecal valve. Description of 7 cases
M Ricci, G Mazzoleni, G Brandi, MC Celli, R Zendron… - Minerva
chirurgica, 1988
COLORECTAL-CANCER IN ULCERATIVE-COLITIS-A PROSPECTIVE COHORT STUDY
IN ITALY G BIASCO, G BRANDI, GM PAGANELLI, FP ROSSINI… -
GASTROENTEROLOGY, 1994
Phase II study of temozolomide and celecoxib in the treatment of
metastatic melanoma R Hakim, R Poggi, M Pantaleo, G Benedetti,
G Brandi… - ASCO Annual Meeting Proceedings, 2006
Chronic ulcerative colitis and colorectal cancer G Biasco, GM
Paganelli, G Brandi, M Miglioli - ACTA ENDOSCOPICA, 1995
Biomarkers of genetic activity in the study of achlorhydric
stomach F Vigagni, P Hrelia, F Maffei, G Biasco, G Brandi… -
Pharmacology and Toxicology-Supplements, 1995
Adamson, RH Agarwal. R. Agarwal, SC 135 Aitken. A. M Azuma, M
Imoto, A Inoue, M Ishikawa, D Ivanyi…
Multivariate prognostic factor analysis in patients (pts) with
advanced biliary tract cancer (aBTC) treated with second-line
chemotherapy (CT) L Fornaro, S Cereda, F Bergamo, F Leone, M
Russano… - EUROPEAN JOURNAL OF CANCER, 2013
Antiprotease Strategy in Pancreatic Cancer Treatment G Brandi,
S Tavolari, T Guarnieri… - 2013
Measurement of rectal cell proliferation by bromodeoxyuridine
uptake and proliferating cell nuclear antigen (PCNA). GM
Paganelli, G Biasco, R Santucci, G Brandi, AA Lalli… - European
Journal of Cancer Prevention, 1993
Intestinal Microbiota around Colorectal Cancer Genesis G
Brandi, F De Rosa, G Liguori, V Agostini…
Occupational exposure to asbestos and cholangiocarcinoma: findings
from an explorative case-control analysis G Brandi, A Farioli,
S Di Girolamo, S Curti, F De Rosa… - Occupational and Environmental
Medicine, 2011
OC-26 The emerging impact of HCC-NAFLD in Italy S Bellentani, A
Brachetti, E Dionigi, A Fracanzani… - Digestive and Liver Disease,
2012
Fulminant hepatitis in a patient with hepatocellular carcinoma
related to nonalcoholic steatohepatitis treated with sorafenib.
G Brandi, S De Lorenzo, S Di Girolamo, S Bellentani… - Tumori,
2014
Genetic heterogeneity in cholangiocarcinoma: a major challenge for targeted therapies. Brandi G, Farioli A, Astolfi A, Biasco G, Tavolari S - Oncotarget, 2015
Efficacy of weekly docetaxel in locally advanced cardiac angiosarcoma. Minichillo S, Pantaleo MA, Nannini M, Coccolo F, Gatto L, Biasco G, Brandi G - BMC Res Notes, 2015
Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). Astolfi A, Urbini M, Indio V, Nannini M, Genovese CG, Santini D, Saponara M, Mandrioli A, Ercolani G, Brandi G, Biasco G, Pantaleo MA - BMC Genomics, 2015
Fungal Dysbiosis in Mucosa-associated Microbiota of Crohn's Disease Patients. Liguori G, Lamas B, Richard ML, Brandi G, da Costa G, Hoffmann TW, Di Simone MP, Calabrese C, Poggioli G, Langella P, Campieri M, Sokol H - J Crohns Colitis, 2016
Estimation of the Survival Benefit Obtainable From Screening for the Early Detection of Pancreatic Cancer. Cucchetti A, Ercolani G, Cescon M, Brandi G, Taffurelli G, Maroni L, Ravaioli M, Pezzilli R, Pinna AD - Pancreas, 2016
Can Current Preoperative Imaging Be Used to Detect Microvascular Invasion of Hepatocellular Carcinoma? Renzulli M, Brocchi S, Cucchetti A, Mazzotti F, Mosconi C, Sportoletti C, Brandi G, Pinna AD, Golfieri R - Radiology, 2016
Cholangiocarcinoma: Current opinion on clinical practice diagnostic and therapeutic algorithms: A review of the literature and a long-standing experience of a referral center. Brandi G, Venturi M, Pantaleo MA, Ercolani G; GICO - Dig Liver Dis, 2016
Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. Brandi G, De Lorenzo S, Nannini M, Curti S, Ottone M, Dall'Olio FG, Barbera MA, Pantaleo MA, Biasco G - World J Gastroenterol, 2016
Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients. Brandi G, Deserti M, Vasuri F, ...; G.I.CO. (Gruppo Italiano Colangiocarcinoma) - Oncologist, 2016
Yttrium-90 radioembolization for unresectable/recurrent intrahepatic cholangiocarcinoma: a survival, efficacy and safety study. Mosconi C, Gramenzi A, Ascanio S, Cappelli A, Renzulli M, Pettinato C, Brandi G, Monari F, Cucchetti A, Trevisani F, Golfieri R - Br J Cancer, 2016
Aspirin for cholangiocarcinoma prevention: New targets to shift the dogma from ascertained risk to possible prevention. Brandi G, De Lorenzo S, Palloni A, Biasco G, Tovoli F - Hepatology, 2017
Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. Marinelli I, Guido A, Fuccio L, Farioli A, Panni V, Giaccherini L, Arcelli A, Ercolani G, Brandi G, ... Anticancer Res, 2017
Microbiota, NASH, HCC and the potential role of probiotics. Brandi G, De Lorenzo S, Candela M, Pantaleo MA, Bellentani S, Tovoli F, Saccoccio G, Biasco G - Carcinogenesis, 2017
Istituto di Ematologia ed Oncologia
Medica
“L.A. Seragnoli” Policlinico
Sant'Orsola-Malpighi
tel 051
2143838
fax 051 2144037
email: giovanni.brandi@unibo.it